Pharmaceutical Policy

Improving the Quality, Safety and Efficiency of Medication Use

While prescription drugs are used by 80% of Americans, the improper, often unsafe use of medications leads to billions of dollars of avoidable healthcare costs. The goal of the CP3 research program is to improve patient and prescriber decision-making, and inform the regulation and coverage of pharmaceuticals. More >


Upcoming Seminar

Join us on 12/4 at noon, when we welcome Stacie Dusetzina, PhD, from Vanderbilt University. This event is co-sponsored by Pitt Public Health, Department of Health Policy and Management.

340B Debate Perspective

In a perspective piece in the New England Journal of Medicine, CP3 Director Walid Gellad and HPI Director Everette James describe the controversy surrounding the 340B Drug Pricing Program.Read more.

Prescribing habits following overdose

In a recent article in JAMA, researchers compared prescription opioid use and medication-assisted treatment rates before and after an overdose. 

Accelerated Drug Approval

In a recent perspective piece in NEJM, Dr. Gellad discusses the accelerated approval process in the era of expensive drugs. Read more.

Addressing the Opioid Epidemic

In a commentary in JAMA Internal Medicine, Dr. Walid Gellad discusses the opioid epidemic within the Nation's Veteran population. 

Physician Peer Networks

In a PLoS One paper, CP3 faculty report that peers strongly influence physician adoption of new drugs.